UK markets close in 3 hours 45 minutes

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.6800-0.0250 (-0.92%)
As of 11:55AM GMT. Market open.
Currency in EUR

Valuation measures

Market cap (intra-day) 597.92M
Enterprise value 3112.75M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)9.65
Price/book (mrq)1.83
Enterprise value/revenue 311.11
Enterprise value/EBITDA 6-29.53

Trading information

Stock price history

Beta (5Y monthly) 0.98
52-week change 3N/A
S&P500 52-week change 313.92%
52-week high 32.7250
52-week low 32.6800
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 533.49M
Float 43.17M
% held by insiders 121.50%
% held by institutions 11.43%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2019
Most-recent quarter (mrq)30 Sep 2020

Profitability

Profit margin -31.65%
Operating margin (ttm)-38.96%

Management effectiveness

Return on assets (ttm)-2.79%
Return on equity (ttm)-4.62%

Income statement

Revenue (ttm)10.15M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)-48.20%
Gross profit (ttm)9.85M
EBITDA -3.82M
Net income avi to common (ttm)-3.21M
Diluted EPS (ttm)-0.0610
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)44.59M
Total cash per share (mrq)0.85
Total debt (mrq)14.62M
Total debt/equity (mrq)18.98
Current ratio (mrq)5.58
Book value per share (mrq)1.46

Cash flow statement

Operating cash flow (ttm)N/A
Levered free cash flow (ttm)N/A